-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, AviadoBio announced the completion of a US$80 million Series A financing
Frontotemporal dementia is the second most common senile dementia after Alzheimer's disease, and there is currently no approved treatment
Note: The original text has been deleted
Reference materials:
[1] AviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform.
[2] Biotech startup AviadoBio emerges with $80M for neuro disorder gene therapies.
[3] Gene therapy startup bursts forth from incubation at J&J and F-Prime, graduating with $80M and a Novartis veteran at the helm.